Hims & Hers (Hims) Q2 Profit 2025

Shares on Hims & Hers Hearly It fell 9% in the long -term trade on Monday after the calf health company announced the results of the second quarter, which missed Wall Street’s expectations for revenue.

Here’s how the company is based on the evaluations of the average analysts composed of LSEG:

• Profit per action: 17 cents adjusted according to 15 cents expected
• Revenue: $ 544.8 million for $ 552 million is expected

Hims & Hers revenue increased by 73% in the second quarter of $ 315.6 million in the same period last year, according to a message. Hims & Hers report a net income of $ 42.5 million, or 17 cents per share, compared to $ 13.3 million, or 6 cents per share, during the same year earlier.

For his third quarter, Hims & Hers said he expects to report revenue between $ 570 million and $ 590 million, while analysts were expecting $ 583 million. The company said its corrected profit before interest, taxes, depreciation and depreciation or EBITDA for the quarter will be between the range of $ 60 million and $ 70 million. Analysts surveyed by Streetaccount were expecting $ 77.1 million.

Hims & Hers has been confronted with disputes in recent months because of its prolonged sale of complex GLP-1Swhich are more expensive, disapproved versions of the blockbuster diabetes and weight loss medicines. Mixed medicines can be made massively when the brand’s treatment is in shortageBut the US Food and Drug Administration declared In February, these supplies problems were solved.

Some televal companies, including Hims and hers, continue to offer complex medicines. It is legal for patients to have access to personalized doses of knockouts in unique cases, such as being allergic to an ingredient in a branded product, for example. Hims & Hers has said Users can still have access to custom doses through its site if they are clinically applicable.

In June, Hims & Hers shares broke over 30% after a short -term cooperation with Novo nordisk broke up. The drug creator said Hims and her “failed to obey the law that prohibits the mass sales of complex drugs” under the “fake concealment” of personalization.

Hims & Hers reported that he was adjusting EBITDA of $ 82 million for its second quarter, as $ 39.3 million last year and over $ 73 million expected by Streetaccount.

Hims & Hers will host his quarterly call with investors at 5:00 pm.

– Anika Kim Constantino of CNBC has contributed to this report.